IRLAB Therapeutics AB (OSTO:IRLAB A) Risk Assessment

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:IRLAB A IRLAB Therapeutics AB OSTO:IRLAB A
35 GF Score
Price kr1.39
GF Value kr11.72
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is IRLAB Therapeutics AB Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of IRLAB Therapeutics AB is: No Data: Cannot be evaluated.

IRLAB Therapeutics AB  (OSTO:IRLAB A) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

IRLAB Therapeutics AB Risk Assessment Related Terms

OSTO:IRLAB A vs VRTX, REGN, ALNY: Risk Assessment Comparison

For the Biotechnology subindustry, IRLAB Therapeutics AB's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IRLAB Therapeutics AB Risk Assessment vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IRLAB Therapeutics AB's Risk Assessment distribution charts can be found below:

* The bar in red indicates where IRLAB Therapeutics AB's Risk Assessment falls into.


OSTO:IRLAB A
35GF Score
IRLAB Therapeutics AB OSTO:IRLAB A
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is IRLAB Therapeutics AB (OSTO:IRLAB A) Overvalued in 2026?

Based on GuruFocus' analysis, IRLAB Therapeutics AB stock appears to be undervalued. The current stock price of kr1.39 is trading 88.2% below its estimated GF Value™ of kr11.72. GuruFocus considers IRLAB Therapeutics AB to be Possible Value Trap.

Key valuation signals for OSTO:IRLAB A:

  • Risk Assessment:
  • GF Value™: kr11.72 vs. price of kr1.39 (88.2% below fair value)
  • GF Score™: 35/100 with 6 warning signs

No single metric tells the full story. See the OSTO:IRLAB A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

IRLAB Therapeutics AB Business Description

Other Exchanges 6IRA:Germany
Address Arvid Wallgren Backe 20, Goteborg, SWE, 413 46
IRLAB Therapeutics AB is a drug discovery and development company providing novel treatments for disorders of the brain. The company focuses on treatments and quality of life for patients with neurological and psychiatric illnesses. It is engaged in programs targeting core dysfunctions in Parkinson's disease and dementias. In addition, it is also involved in the clinical development of novel compounds that aims to offer improved clinical benefit for patients with Parkinson's disease. The company's current clinical candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which have successfully gone through Phase I safety and Phase IIa efficacy proof-of-concept studies, are now in Phase IIb trials.
35GF Score

Get the complete analysis for OSTO:IRLAB A

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.39
Price
kr11.72
GF Value